Skip to content

Pillar Therapeutics

Oligonucleotide medicines for hard-to-reach tissues

Raised to date

$14M

of $25M offered across 1 Form D filing

Still open
$11M
Investors
2
Last filed
May 13, 2026

About

Pillar Therapeutics is a stealth-mode biotechnology company incubated by RA Capital's Raven in Boston. It is building a platform to deliver oligonucleotide therapeutics with high precision to cells beyond the liver, muscle and kidney, with a focus on undruggable genes. It raised a $14M seed in April 2026.

Targets oligonucleotide delivery to tissues outside the liver, muscle and kidney.

Funding

  • EquityFiled May 13, 2026Form D
    $14M/ $25M

Product

Oligonucleotide delivery platform

Therapeutics platform

A platform to deliver oligonucleotides precisely to previously untargeted cells, aimed at undruggable genes alone or combined with validated targets.

  • Oligo-based modalities for tissues beyond liver, muscle and kidney
  • Focus on undruggable genes

Built for

Patients with diseases in tissues beyond the liver, muscle and kidney

People on file